Bank Julius Baer & Co’s NLS Pharmaceutics Warrant NLSPW Stock Holding History

Bank Julius Baer & Co’s Portfolio NLSPW Stock Details NLSPW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-7,370	Closed	-$6K	–	725
2021 Q4	$6K	Hold	7,370	–	–	﹤0.01%	803
2021 Q3	$6K	Buy	7,370 +78	+1%	+$72	﹤0.01%	791
2021 Q2	$7K	Buy	+7,292	New	+$6.46K	﹤0.01%	793

Other funds holding NLSPW

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return

EAM

Empery Asset Management New York $83M AUM

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank Julius Baer & Co's NLSPW Position: Q1 2022 in Review

Bank Julius Baer & Co sold out of NLS Pharmaceutics Warrant (NLSPW) in Q1 2022, closing a stake of 7,370 shares — an estimated $6K sold.

Bank Julius Baer & Co first reported a position in NLSPW in Q2 2021 and held it in 3 quarters. The position peaked at $7K in Q2 2021. 8 funds tracked by Wall St. Rank hold NLSPW as of Q1 2022.

Bank Julius Baer & Co reported no remaining NLS Pharmaceutics Warrant position as of Q1 2022 after selling out during the quarter.
Bank Julius Baer & Co sold 7,370 NLS Pharmaceutics Warrant shares in Q1 2022, an estimated $6K.
Bank Julius Baer & Co first reported a position in NLS Pharmaceutics Warrant in Q2 2021 and held it in 3 quarters.
Bank Julius Baer & Co's NLS Pharmaceutics Warrant position peaked at $7K in Q2 2021.
8 funds tracked by Wall St. Rank held NLS Pharmaceutics Warrant as of Q1 2022.

Based on Bank Julius Baer & Co's 13F filing for Q1 2022, filed 9 May 2022.